Clinical Trial Update: DOTAREM®-Enhanced MRA Compared to GADOVIST®-Enhanced MRA in Patients With Abdominal or Lower Limb Arterial Diseases [Phase 4]

View source ↗

Summary

Phase 4 head-to-head trial comparing DOTAREM-enhanced MRA with GADOVIST-enhanced MRA in patients with peripheral arterial disease; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral Arterial Disease

Drugs mentioned

• DOTAREM (Gadoterate meglumine)
• Gadovist (gadobutrol)

Snippet

Sponsor: Guerbet | Conditions: Peripheral Arterial Disease | Phase 4 | Status: COMPLETED | Results posted: 2012-11-02